All you need to know about Australia’s burgeoning medicinal cannabis industry

The Australian medicinal cannabis market continues its strong growth trajectory, with experts anticipating the industry would grow faster than predicted earlier. Increased clinical research worldwide will likely encourage domestic regulators and doctors to expand the range of indications that can be treated by using medical cannabis.

Moreover, advances in medical cannabis technology, for instance, custom cannabinoids for specific indications, are expected to further boost the acceptance of medical cannabis in the market. Medicinal cannabis products are available in the form of pills, nasal sprays, and oils, among other formations. The products can be used to treat several indications, including epilepsy, multiple sclerosis, chronic pain, and side effects related to chemotherapy, though access to cannabis products is strictly limited.

In December 2020, the Therapeutic Goods Administration (TGA) revealed its final decision of down-scheduling certain low dose CBD formulations from Schedule 4 to Schedule 3, i.e. from prescription medicine to pharmacist only medicine. With this decision, TGA approved low-dose CBD containing products (up to a maximum of 150 mg/day) can be provided as over-the-counter (OTC) medicine for use in adults without any prescription.

Australia is moving ahead in its developing medical cannabis industry. However, in the country, patients still confront challenges that affect the entire market. Until now, medical cannabis products are not registered as a medicine in Australia, so patients have to use special pathways (Special Access Scheme) to access the drug, and it can be a lengthy process.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK